NGeneBio Co., Ltd of Seoul at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Manufacturers

NGeneBio Co., Ltd

303-307, Daeryung Post Tower 1, 288 Digital-ro, Guro-gu, 08390 Seoul
Korea, Republic
Telephone +82-70-4224-6554
Fax +82-866-9784
business@ngenebio.com

This company is co-exhibitor of
Korea Medical Devices Industrial Coop. Association (KMDICA)

Hall map

MEDICA 2019 hall map (Hall 7a): stand C09

Fairground map

MEDICA 2019 fairground map: Hall 7a

Contact

Megan Kim

Seoul

Phone
+82-70-4224-6554

Email
megan.kim@ngenebio.com

YoungJoon Moon

Phone
+82-70-4435-8106

Email
business@ngenebio.com

Our products

Product category: DNA testing

NGS Breast Cancer kit, BRCAaccuTest™PLUS for BRCA1/2 mutation genes detection

BRCAaccuTestT™PLUS is a next-generation sequencing (NGS)-based in vitro diagnostic (IVD) product which detects mutations in BRCA1 /BRCA2 genes. BRCAaccuTest™ consists of NGS panel for detecting variants and clinical data analysis software (S/W). Rapid and precise detection of various mutations in BRCA 1/2 with NGS can be accomplished and the user-oriented analysis software enables convenient generation of clinical report. We have received CE-IVD and ISO 13485 i

More Less

Product category: DNA testing

NGS Solid Cancer kit, SOLIDaccuTest™ for Lung | Gastric | Colon | Breast and Ovarian Cancer & Melanoma, etc.

SOLIDaccuTestTM is designed to explorer genetic variants associated with solid tumors using NGS technology. It reflected the latest research trends and is optimized for the medical purpose by selecting essential genes for solid cancer diagnosis.

More Less

Product category: DNA testing

NGS Hematological Malignancies kit, HEMEaccuTest™ for Acute Myeloid Leukemia (AML) | Acute Lymphoid Leukemia (ALL) | Multiple Myeloma (MM) Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN) | Lymphoma

Hematologic malignancy refers to malignant tumors that occur in blood, blood vessels, lymph nodes, lymphatic organs, and constitute a variety of gene instability such as gene mutation, rearrangement, and amplification.
While existing gene analysis technology only confirms the presence of certain mutations in cancer genes, diagnosis using NGS technology makes it possible to analyze the major gene mutation patterns of patients and identify the side-by-side variations to enable personalized diagnosis. HEMEaccuTest™ is a product for detecting and analyzing mutations in blood cancer-related genes using NGS. we have received CE-IVD in 2018.

More Less

Product category: DNA testing

NGS HLA typing kit, HLAaccuTest

-New Launched Product (CE-IVD planned in 4Q/2019)
-Complete workflow for NGS HLA typing: NGS panel kit (HLAaccuTestTM) & analysis SW (EasyHLAanalyzerTM) – TAT 3 days
-Comprehensive primer coverage for 11 HLA loci, matching IMGT/HLA DB
-Automatic NGS data analysis and individual allele assignments
-Easy-to-use, user-friendly UI and intuitive operation

More Less

Product category: DNA testing

NGS Analysis Software, NGeneAnalySys™

NGeneAnalySys™ is a software for analysis of the genetic testing data produced by next-generation sequencing (NGS) and helps to report in clinical-grade for oncology test.
It provides accurate pathogenic variants information based on ACMG guideline and relevant therapy information based on databases (solid tumor / hematologic malignancies), which enables efficient on-site data analysis for clinical NGS.
It is CE-IVD marked with BRCAaccuTest(Breast/Ovarian cancer).

More Less

Product category: DNA testing

DNA profiling kit, IDaccuTest™ for Paternity test | Forensic DNA analysis | Chimerism test

-STR Technology:
DNA regions with short repeat units (usually 2-7 bp in length) are called Short Tandem Repeats (STR). STRs are found surrounding the chromosomal centromere (the structural center of the chromosomes). STRs have proven to have several benefits that make them especially suitable for human identification. STRs have become well-known DNA markers for genetic profiling since they are easily amplified by polymerase chain reaction (PCR); the PCR products of STRs are generally consisteet in amount, making analysis easier. The smaller size of STR alleles is suitable for use in forensic applications, since DNA degradation in common in forensic samples, interfering PCR amplifications. The small target amplificaiton of STR and overcome the difficulty in forensic DNA samples.

-Product list
Autosomal STR (A-STR) - IDaccuTest A-STR 16plex, IDaccuTest A-STR 9plex
Chromosome STR (Y-STR) - IDaccuTest Y-STR

More Less

Company news

Date

Topic

Download

Aug 4, 2019

AACC (American Association Clinical Chemistry)2019 Exhibition

AACC (AMERICAN ASSOCIATION for CLINICAL CHEMISTRY) Annual Scientific Meeting & Clinical Lab Expo is a worldwide outstanding event showcases the cutting-edge science and technology shaping the future of laboratory medicine including molecular diagnostics. The 71st AACC Clinical Lab Expo will be held in Anaheim, California, August 4-8, 2019. NGeneBio will participate in AACC Clinical Lab Expo introducing Next Generation Sequencing (NGS)-based clinical diagnostic products, clinical NGS analysis software and short tandem repeat (STR) genetic testing products.

Pleases visit us at booth #674.
For more information on AACC 2019, please visit https://www.2019aacc.org/

More Less

Feb 25, 2019

NGeneBio Raises $11M

NEW YORK (GenomeWeb) – Korean diagnostics firm NGeneBio said this week that it recently closed an $11 million Series B financing.
The company also achieved a CE-IVD mark for its HEMEaccuTest, which targets hematological malignancies, according to YoungJoon Moon, director of business development for the Seoul-based company.
NGeneBio’s new financing builds on the $1.9 million it raised last year with Korea Investment Partners. Seoul-based KIP returned for the latest round along with UTC Investment, IMM Investment, and DSC Investment, all three of which are also based in Korea.
Moon said that NGeneBio will use the proceeds to expand its presence in the next-generation sequencing-based precision medicine market, as well as in new product development, including investments in clinical studies and filings with regulatory entities.

Dec 03, 2018

More Less